Small Molecules
26 September 2016
Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy26 September 2016
Array BioPharma and Pierre Fabre Announce COLUMBUS Phase 3 Study of Encorafenib plus Binimetinib For BRAF-Mutant Melanoma Met Primary Endpoint26 September 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma26 September 2016
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome24 September 2016
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions24 September 2016
US FDA approves labeling update of Rexulti® (brexpiprazole) for maintenance treatment of schizophrenia24 September 2016
Headline conclusions from the first out of three phase III studies on idalopirdine in Alzheimer’s disease23 September 2016
Faraday Pharmaceuticals Announces First-In-Human Trial of FDY-530123 September 2016
MIV-711 Osteoarthritis Trial: Recommendation to Go Ahead based on independent review of safety data, and first patient enrolled in extension study23 September 2016
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients22 September 2016
Neuraltus Pharmaceuticals Initiates Confirmatory Phase 2 Study of NP001 in Patients with Amyotrophic Lateral Sclerosis22 September 2016
Turing Pharmaceuticals AG Announces Development of New Drug Candidates for Toxoplasmosis22 September 2016
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease22 September 2016
Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder22 September 2016
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis22 September 2016
ATB-346 Shows Promising Results in Experimental Melanoma22 September 2016
Teva Announces Positive Top-Line Data from Second Phase III Study of SD-809 in Tardive Dyskinesia (TD)22 September 2016
Newron re-submits US NDA for Xadago® (safinamide)22 September 2016
Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell DiseaseNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports